Wedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price Target

Benzinga · 2d ago
Wedbush analyst David Nierengarten reiterates Aktis Oncology (NASDAQ:AKTS) with a Outperform and maintains $35 price target.